ABCG2 and hepatocellular carcinoma: Therefore, this study aimed to investigate the causal relationship between BCRP/ABCG2 expression and sorafenib sensitivity, and to examine whether BCRP/ABCG2 inhibition is a potential strategy to sensitize HCC cells to sorafenib.